.jpg)
.png)
NLA News
Part Two Provides New Recommendations for Managing Cholesterol in Diverse and Underrepresented Ethnic and Racial Groups along with Recommendations that Cross the Life Span from Children to Seniors CHICAGO — Today, the National Lipid Association (NLA) released a draft of its Part... more
Newly Defined Term Lipid Specialist Aims to Formalize Medical Specialty, Enhance Public Understanding of Blood Fat Disorders and Optimal Treatment MIAMI, Fla. – (May 17, 2019) -- With the Centers for Disease Control and Prevention (CDC) indicating more than 95 million adults age 20 or... more
The USAGE Campaign, which launched in 2012 as a joint initiative by the NLA, Kowa Pharmaceuticals America and Eli Lilly & Co., recently was honored with finalist designation for two major industry awards, the PRSA National Silver Anvil and the PRSA Big Apple Awards. The USAGE Campaign... more
JACKSONVILLE, Fla. – (January 6, 2021) -- The National Lipid Association (NLA) is proud to announce that it has achieved reaccreditation status from Joint Accreditation for Interprofessional Continuing Education for a new six-year term through November 2026. This recent reaccreditation enables the... more
Emphasizes the Importance of LDL-Cholesterol Monitoring, LDL Goal Attainment and Shared Decision Making Between Patients and Provider NEW YORK — Yesterday, the National Lipid Association (NLA) released the Full Report of its Part One Recommendations for Patient-Centered Management of... more
Call for Nominations is open for the National Lipid Association Board of Directors and Chapter officers and will be extended until 5 pm ET on February 15, 2025. To submit a nomination and for more information on the process, visit lipid.org/nominate. Colleagues can be nominated... more
On February 7, 2015, the National Lipid Association (NLA) Strategic Planning Committee (Committee) convened in Orlando, Florida. The Committee reaffirmed the mission and goals of the organization, and assigned the following as the priorities and deadlines: Based on the February 7, 2015,... more
MIAMI, Fla. – (May 18, 2019) – Findings of the first patient statin use survey based on a comprehensive set of patient experiences and behavioral markers were presented today at the National Lipid Association’s (NLA) 2019 Scientific Sessions. The Statin Adverse Treatment... more
Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) approved EvkeezaTM (evinacumab-dgnb) as an adjunct to other low-density lipoprotein cholesterol (LDL-C) lowering therapies to treat adult and pediatric patients aged 12 years and older with... more
September 24 is Familial Hypercholesterolemia (FH) Awareness Day. It was initiated by the FH Foundation as part of their mission to raise awareness of FH in the public. As a supporter of this initiative, the National Lipid Association (NLA) and the Foundation of the NLA would like to help... more